Pharma Capital

ImmuPharma chairman 'delighted' with £4.1mln fund raise support

Tim McCarthy, chairman of ImmuPharma PLC (LON:IMM) talks to Proactive about the company's £4.1mln raise from investors after an oversubscribed placing.

The new cash infusion is to be used to strengthen its balance sheet as negotiations take place with potential commercial partners for its flagship drug, Lupuzor.

 

View full IMM profile

ImmuPharma PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.